Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Article Insider Buying: Smart Money Just Spent +$100M on These 3 StocksAuthor: Leo Miller. Originally Published: 1/1/2026. 
Key Takeaways - DoorDash saw a rare nine-figure open-market buy tied to Sequoia Capital, a strong confidence signal—but it should be weighed against routine executive selling.
- Kenvue’s recent buying looks less like a standalone consumer-health bet and more like a view on the pending Kimberly-Clark deal and closing dynamics.
- Kymera’s $172 million add from Baker Bros followed encouraging KT-621 trial data, but the program is still early and carries typical clinical-stage biotech risk.
Insider buying can be one of the cleanest "follow-the-money" signals in the market. Over the past month, three names have stood out for more than $100 million in purchases tied to prominent funds and well-known professional investors. The takeaway: these trades don't guarantee upside by themselves, but they can reveal where sophisticated capital sees mispriced risk—or where a catalyst (such as a merger) may be creating an opportunity. Leading Venture Firm Makes $100 Million DoorDash Purchase Wall Street Legend Who Called 2022 Bear Issues New Warning
50-year Wall Street legend Marc Chaikin called the 2022 bear market, the 2023 bank failures, the 2020 crash, and the 2025 tariff tantrum – all in advance. In light of the recent volatility, he's now stepping forward to warn of a "violent market shift" headed straight for U.S. stocks in early 2026. Here's how to prepare. First up is the delivery platform DoorDash (NASDAQ: DASH). On Nov. 25 and Nov. 26, board member Alfred Lin purchased a total of just over $100 million worth of DoorDash shares. As detailed in Lin's Form 4 SEC filings, the shares were not bought for his personal account. Column 7 of these filings shows beneficial ownership was assigned to an investment fund managed by Sequoia Capital, where Lin is a partner. That detail supports a bullish read: Sequoia purchased on behalf of its clients, and investing other people's money typically invites additional scrutiny. Sequoia is unlikely to have made such large purchases lightly. Context matters, however. Since those purchases, DoorDash insiders have sold about $29.5 million of stock. All of those sales occurred under predetermined 10b5-1 plans, which limits their bearish implications. Starboard Buys KVUE Amid Kimberly-Clark Deal The $33 billion consumer staples company Kenvue (NYSE: KVUE) has also seen sizable insider buying. On Dec. 11 and Dec. 12, board member Jeffrey C. Smith purchased roughly $111 million worth of Kenvue shares, with investment fund Starboard Value LP listed as the beneficial owner of the shares. Kenvue owns a range of over-the-counter drugs and personal care brands, including Tylenol, Band-Aid, and Neutrogena. On Nov. 3, Kenvue announced its acquisition by consumer staples giant Kimberly-Clark (NASDAQ: KMB) in a cash-and-stock deal, with the parties guiding toward a second-half-2026 close pending approvals. Kenvue shareholders will receive a portion of the consideration in Kimberly-Clark shares, so the ultimate value they get depends in part on Kimberly-Clark's share price before closing. Kimberly-Clark shares fell nearly 15% after the Nov. 3 announcement. Starboard's purchase looks more like a bet on Kimberly-Clark than on Kenvue's standalone prospects. Starboard likely views the sell-off as overdone and expects Kimberly-Clark to recover ahead of the deal closing, which would increase the value Kenvue investors receive. Biotech Investor Ups KYMR Position Significantly After Positive Trial Data Kymera Therapeutics (NASDAQ: KYMR) has seen the most insider buying of any stock in the last 30 days. On Dec. 11, Baker Bros. Advisors LP purchased $172.5 million worth of Kymera shares. Baker Bros.' latest 13F filing shows the firm's portfolio is concentrated heavily in biotech names. Baker Bros.' purchase followed a near 42% surge in Kymera shares on Dec. 8, when the company released positive Phase 1b results for its experimental drug KT-621, being developed for atopic dermatitis (eczema). The firm added just over 2 million Kymera shares, increasing its position by roughly 30%—a clear vote of confidence from this institutional investor. These trial results are early-stage, so KT-621 remains far from commercial viability. Still, at least one major institution appears to see meaningful upside. Investors should also note Kymera has experienced about $21.6 million in non-10b5-1 sales since the results, a counterweight to Baker Bros.' bullish purchase that bears consideration. Smart Money Sends Optimistic Signals for DASH, KVUE, and KYMR Clearly, the smart money is placing significant bets on DASH, KVUE, and KYMR. While these purchases should not be viewed in isolation, they are meaningful bullish signals that highlight where sophisticated investors see opportunity.
| 
